Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b
Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
4 months since company announcement on 2 September 2024.
IMO, Management would be finalizing an abstract submission within the next few weeks for the AACR meeting from April 25 to 30, 2025.
Expecting an Azer-cel update before the abstract being accepted.
Regards.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
28.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.77M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 27.0¢ | $461.4K | 1.681M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 134437 | 7 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |